ZARONTIN DIN 00022799
Health Canada record
| Active ingredient(s) | ETHOSUXIMIDE 250 MG |
|---|---|
| Dosage form | Capsule |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | N03AD01 ETHOSUXIMIDE |
| Original market date | 31-Dec-1960 |
| Current status date | 11-Oct-2022 |
| Source | Health Canada DPD |
Establishment licence of the holder
Searchlight Pharma Inc — licence 102247, currently licensed, last inspection rating C (2024-10-10).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing ETHOSUXIMIDE
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02545772 | MAR-ETHOSUXIMIDE | MARCAN PHARMACEUTICALS INC | Capsule | ETHOSUXIMIDE 250 MG | Marketed |
| 02547171 | ODAN-ETHOSUXIMIDE | ODAN LABORATORIESLTD | Capsule | ETHOSUXIMIDE 250 MG | Marketed |
| 00023485 | ZARONTIN SYRUP | SEARCHLIGHT PHARMA INC | Syrup | ETHOSUXIMIDE 250 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 2240 | 2001-01-11 | New Drug Submission (NDS) | MANUFACTURER NAME CHANGE |
International API supply for ETHOSUXIMIDE
1 valid EDQM Certificates of Suitability from 1 holders. 1 active FDA Drug Master Files.
Request a quote for ZARONTIN